Ampio Pharmaceuticals, Inc. (AMPE): Price and Financial Metrics


Ampio Pharmaceuticals, Inc. (AMPE): $0.28

0.00 (-1.23%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AMPE to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

AMPE Stock Price Chart Interactive Chart >

Price chart for AMPE

AMPE Price/Volume Stats

Current price $0.28 52-week high $9.71
Prev. close $0.28 52-week low $0.20
Day low $0.28 Volume 141,464
Day high $0.29 Avg. volume 211,949
50-day MA $0.30 Dividend yield N/A
200-day MA $1.63 Market Cap 4.23M

Ampio Pharmaceuticals, Inc. (AMPE) Company Bio


Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. It is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds. The company's product pipeline includes Ampion, which is in phase III clinical trial, is an intra-articular injection for the treatment of osteoarthritis of the knee. Ampio Pharmaceuticals, Inc. has collaborative research agreements to explore new clinical indications for its immunomodulatory drug, Ampion. The company is headquartered in Englewood, Colorado.


AMPE Latest News Stream


Event/Time News Detail
Loading, please wait...

AMPE Latest Social Stream


Loading social stream, please wait...

View Full AMPE Social Stream

Latest AMPE News From Around the Web

Below are the latest news stories about AMPIO PHARMACEUTICALS INC that investors may wish to consider to help them evaluate AMPE as an investment opportunity.

AMPIO PHARMACEUTICALS ISSUES LETTER TO STOCKHOLDERS

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company") today released the following letter to stockholders from its Chairman, Kevin Buchi and Chief Executive Officer, Mike Martino.

Yahoo | January 17, 2023

Ampio Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company") today announced that it has received notification from The NYSE American LLC ("NYSE American") stating that the Company has regained compliance with the NYSE American's continued listing standards. Specifically, the Company has resolved the continued listing deficiency with respect to its low selling price as described in Section 1003(f)(v) of the NYSE American Company Guide.

Yahoo | December 27, 2022

Ampio Pharmaceuticals Announces NYSE American Removal of Trading Suspension

Ampio Pharmaceuticals, Inc. (NYSE American/OTC Pink: AMPE) (the "Company") received notification from NYSE American LLC ("NYSE American" or the "Exchange") stating that the staff of NYSE Regulation has withdrawn its delisting determination and will be lifting the trading suspension of the Company's common stock on the NYSE American.

Yahoo | November 17, 2022

Ampio Pharmaceuticals Announces Fifteen-to-One Reverse Stock Split

Ampio Pharmaceuticals, Inc. (NYSE American/OTC Pink: AMPE), announced today that effective November 9, 2022 at 4:01 p.m. Eastern Time, the Company will amend its certificate of incorporation to implement a fifteen-to-one reverse stock split.

Yahoo | November 8, 2022

Ampio Pharmaceuticals Announces NYSE American Has Commenced Delisting Proceedings

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company") received written notification from NYSE American LLC ("NYSE American" or the "Exchange") stating that the staff of NYSE Regulation has determined to commence proceedings to delist the Company's common stock from the Exchange. Trading in the Company's common stock was suspended.

Yahoo | October 4, 2022

Read More 'AMPE' Stories Here

AMPE Price Returns

1-mo 26.01%
3-mo -42.39%
6-mo -87.72%
1-year -96.17%
3-year -97.26%
5-year -99.31%
YTD 24.33%
2022 -97.37%
2021 -64.15%
2020 172.73%
2019 47.59%
2018 -90.29%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6981 seconds.